TY - JOUR
T1 - Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta
AU - Wynne, Brandi M.
AU - Labazi, Hicham
AU - Carneiro, Zidonia N.
AU - Tostes, Rita C.
AU - Webb, R Clinton
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/11/5
Y1 - 2017/11/5
N2 - Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.
AB - Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.
KW - Angeli's Salt
KW - Endothelin-1
KW - HNO
KW - Nitroglycerin
KW - Vascular dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85028695168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028695168&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2017.08.024
DO - 10.1016/j.ejphar.2017.08.024
M3 - Article
C2 - 28830679
AN - SCOPUS:85028695168
SN - 0014-2999
VL - 814
SP - 294
EP - 301
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -